Patients Aged 18 Years And Older With Relapsed Or Refractory Flt3 Mutated Acute Myeloid Leukemia clinical trials

Explore recruiting patients aged 18 years and older with relapsed or refractory flt3 mutated acute myeloid leukemia clinical trials.

Also recruiting in Europe

Patients Aged 18 Years And Older With Relapsed Or Refractory Flt3 Mutated Acute Myeloid Leukemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

FILOAML-RR-01-OGILAR: Open-label, phase 2 study investigating the efficacy and safety of the addition of oral-azacitidine to salvage treatment by gilteritinib in subjects ≥18 years of age with relapsed/refractory FLT3-mutated acute myeloid leukemia

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Patients Aged 18 Years And Older With Relapsed Or Refractory Flt3 Mutated Acute Myeloid Leukemia trials by city

Patients Aged 18 Years And Older With Relapsed Or Refractory Flt3 Mutated Acute Myeloid Leukemia in Toronto Patients Aged 18 Years And Older With Relapsed Or Refractory Flt3 Mutated Acute Myeloid Leukemia in Vancouver Patients Aged 18 Years And Older With Relapsed Or Refractory Flt3 Mutated Acute Myeloid Leukemia in Montreal Patients Aged 18 Years And Older With Relapsed Or Refractory Flt3 Mutated Acute Myeloid Leukemia in Calgary Patients Aged 18 Years And Older With Relapsed Or Refractory Flt3 Mutated Acute Myeloid Leukemia in Edmonton Patients Aged 18 Years And Older With Relapsed Or Refractory Flt3 Mutated Acute Myeloid Leukemia in Ottawa Patients Aged 18 Years And Older With Relapsed Or Refractory Flt3 Mutated Acute Myeloid Leukemia in Winnipeg Patients Aged 18 Years And Older With Relapsed Or Refractory Flt3 Mutated Acute Myeloid Leukemia in Quebec City Patients Aged 18 Years And Older With Relapsed Or Refractory Flt3 Mutated Acute Myeloid Leukemia in Hamilton Patients Aged 18 Years And Older With Relapsed Or Refractory Flt3 Mutated Acute Myeloid Leukemia in Kitchener Patients Aged 18 Years And Older With Relapsed Or Refractory Flt3 Mutated Acute Myeloid Leukemia in London Patients Aged 18 Years And Older With Relapsed Or Refractory Flt3 Mutated Acute Myeloid Leukemia in Halifax Patients Aged 18 Years And Older With Relapsed Or Refractory Flt3 Mutated Acute Myeloid Leukemia in New York Patients Aged 18 Years And Older With Relapsed Or Refractory Flt3 Mutated Acute Myeloid Leukemia in Los Angeles Patients Aged 18 Years And Older With Relapsed Or Refractory Flt3 Mutated Acute Myeloid Leukemia in Chicago Patients Aged 18 Years And Older With Relapsed Or Refractory Flt3 Mutated Acute Myeloid Leukemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease